Arthritis
What the FAA's documents say about arthritis, in plain words, with the FAA's own words one press away.
Short version
The FAA's table sorts it into three rows.
| Situation | What the examiner does | Pathway |
|---|---|---|
| Row AOsteoarthritis that is well controlled, with no persistent daily symptoms, no functional limitations, and treatment with NSAIDs or anti-inflammatory medication only. | Examiner issues | Examiner can issue |
| Row BOsteoarthritis on additional medication, or autoimmune arthritis. | Worksheet | CACI |
| Row CAll others. The row names complications, symptoms, or an underlying cause with complications or systemic disease, etc. | Defers to the FAA | Special Issuance |
Show the FAA's words: the FAA's table for Arthritis
- Row A · Examiner can issue
Osteoarthritis that is well controlled, with no persistent daily symptoms, no functional limitations, and treatment with NSAIDs or anti-inflammatory medication only. The table says ISSUE, and has the examiner summarize this history and annotate Block 60.
A. Osteoarthritis … Well controlled, no persistent daily symptoms; No functional limitations; and Treatment is NSAIDS or anti-inflammatory medication only. … ISSUE Summarize this History, annotate Block 60.
- Row B · CACI
Osteoarthritis on additional medication, or autoimmune arthritis. The table sends the examiner to the CACI worksheet for arthritis and says this will require a current, detailed clinical progress note, and the hydroxychloroquine (HCQ)/chloroquine (CQ) status summary (Plaquenil/Aralen) if taking Plaquenil. It has the examiner annotate Block 60.
B. Osteoarthritis on additional medication OR Autoimmune arthritis … See CACI worksheet This will require a current, detailed clinical progress note. and Hydroxychloroquine (HCQ)/ Chloroquine (CQ) Status Summary (Plaquenil/Aralen) if taking plaquenil. … Follow the CACI - Arthritis Worksheet Annotate Block 60.
- Row C · Special Issuance
All others. The row names complications, symptoms, or an underlying cause with complications or systemic disease, etc. The table lists what to submit to the FAA for review. The examiner defers and submits the information to the FAA for a possible Special Issuance.
C. All others … Complications*; Symptomatic; or Underlying cause with complications or systemic disease, etc. … Submit the following to the FAA for review: … DEFER Submit the information to the FAA for a possible Special Issuance.
- A note on the table, 1
The table says complications include joint deformity or decreased range of motion or strength that would impair flight duties, and systemic disease.
*Complications include: • Joint deformity or decreased range of motion or strength that would impair flight duties • Systemic disease
The FAA pathways for arthritis
- How this pathway works: Examiner can issueNo special pathwayRow A
- How this pathway works: CACIConditions AMEs Can IssueRow B
- How this pathway works: Special IssuanceAuthorization for Special Issuance of a Medical CertificateRow C
- How this pathway works: AASIAME Assisted Special IssuanceAfter the FAA decides
Which exam
Your step-by-step plan
Step 1: The progress note from the treating doctor or specialist
The note the examiner reviews, and what the worksheet looks for in it.Within 90 days before the examA current, detailed progress note from a clinic visit with your treating physician or specialist, no more than 90 days before the exam. Your AME reviews it.
What your treating physician finds
- Stable on the current regimen, with no changes recommended
- No symptoms, or mild to moderate symptoms with no significant limitations to range of motion, lifestyle or activities
Acceptable causes
- Osteoarthritis
- Autoimmune, limited to rheumatoid (limited to joint), psoriatic, or ankylosing spondylitis
For osteoarthritis the worksheet points to the disposition table and says a CACI may not be required.
Show the FAA's words: The progress note from the treating doctor or specialist
the AME must review a current, detailed Clinical Progress Note generated from a clinic visit with the treating physician or specialist no more than 90 days prior to the AME exam.
FAA source: CACI – Arthritis Worksheet. FAA date 29 April 2026; checked by Crosscheck 14 October 2026.
Treating physician finds the condition stable on current regimen and no changes recommended
FAA source: CACI – Arthritis Worksheet. FAA date 29 April 2026; checked by Crosscheck 14 October 2026.
Symptoms [ ] None or mild to moderate symptoms with no significant limitations to range of motion, lifestyle, or activities
FAA source: CACI – Arthritis Worksheet. FAA date 29 April 2026; checked by Crosscheck 14 October 2026.
Cause of Arthritis *Osteoarthritis - see Arthritis Disposition Table CACI may not be required. Acceptable causes are limited to: [ ] Osteoarthritis* and/or [ ] Autoimmune to include only the following: rheumatoid (limited to joint), psoriatic, or ankylosing spondylitis
FAA source: CACI – Arthritis Worksheet. FAA date 29 April 2026; checked by Crosscheck 14 October 2026.
Step 2: Medications
The medications the worksheet lists, and the status summary for hydroxychloroquine.One question insideYour arthritis medications
One or more of the medications the worksheet lists, with or without daily NSAIDs.
One or more of
- Prednisone (an oral steroid), 20 mg/day equivalent or less
- Azathioprine (Imuran)
- Methotrexate (Trexall)
- Sulfasalazine (Azulfidine)
- Hydroxychloroquine or chloroquine (Plaquenil/Aralen), with the status summary
- Any single medication from the list below, after a 2-week ground trial
Post-dose observation time
- None
- Apremilast (Otezla), baricitinib (Olumiant), tofacitinib (Xeljanz), upadacitinib (Rinvoq)
- 4 hours
- Adalimumab (Humira and all biosimilars), certolizumab (Cimzia), etanercept (Enbrel), golimumab (Simponi), anakinra (Kineret), guselkumab (Tremfya), ixekizumab (Taltz), risankizumab (Skyrizi), sarilumab (Kevzara), secukinumab (Cosentyx), tocilizumab (Actemra), ustekinumab (Stelara)
- 24 hours
- Infliximab (Inflect, Remicade, Renflexis), abatacept (Orencia)
- 72 hours
- Rituximab (Rituxan)
Hydroxychloroquine (HCQ)/chloroquine (CQ) status summary
A hydroxychloroquine (HCQ)/chloroquine (CQ) status summary (Plaquenil/Aralen) that is favorable, with no concerns.
Show the FAA's words: Medications
[ ] One or more of the following with or without daily NSAIDs: Oral steroid prednisone 20 mg/day equivalent or less (see steroid conversion calculator) azathioprine (Imuran) methotrexate (Trexall) sulfasalazine (Azulfidine) Hydroxychloroquine (HCQ)/Chloroquine (Plaquenil/Aralen) see status report requirement below** Any singe medication listed below after a 2-week ground trial and:
FAA source: CACI – Arthritis Worksheet. FAA date 29 April 2026; checked by Crosscheck 14 October 2026.
Any singe medication listed below after a 2-week ground trial and: No post-dose observation time: PDE4: apremilast (Otezla) JAK: baricitinib (Olumiant); tofacitinib (Xeljanz); upadacitinib (Rinvoq) 4-hour post-dose observation time: TNF: adalimumab (Humira and all biosimilars), certolizumab (Cimzia), etanercept (Enbrel), golimumab (Simponi) IL: anakinra (Kineret), guselkumab (Tremfya), ixekizumab (Taltz), risankizumab (Skyrizi), sarilumab (Kevzara), secukinumab (Cosentyx), tocilizumab (Actemra), ustekinumab (Stelara) Other post-dose observation time: 72-hour rituximab (Rituxan) 72-hour - CD20 24 hours: infliximab (Inflect, Remicade, Renflexis) - TNF 24 hours: abatacept (Orencia) – T-Cell
FAA source: CACI – Arthritis Worksheet. FAA date 29 April 2026; checked by Crosscheck 14 October 2026.
** STATUS SUMMARY is required if Hydroxychloroquine (HCQ)/ Chloroquine (CQ) (Plaquenil/Aralen) is used. [ ] Hydroxychloroquine (HCQ)/ Chloroquine (CQ) Status Summary (Plaquenil/Aralen) is favorable and no concerns OR [ ] N/A (NOT taking hydroxychloroquine/chloroquine [Plaquenil/Aralen])
FAA source: CACI – Arthritis Worksheet. FAA date 29 April 2026; checked by Crosscheck 14 October 2026.
Please have the ophthalmologist or optometrist who monitors your medication provide the requested information in the space provided. Return this status summary to your AME for electronic upload to the FAA.
FAA source: Plaquenil Status Report (hydroxychloroquine / chloroquine). FAA date 25 September 2024; checked by Crosscheck 14 October 2026.
What the examiner checks
It depends on which row of the FAA's table describes the case.
Row AExaminer issuesExaminer can issue
The table says ISSUE, and has the examiner summarize this history and annotate Block 60.
Row BWorksheetCACI
The table sends the examiner to the CACI worksheet for arthritis and says this will require a current, detailed clinical progress note, and the hydroxychloroquine (HCQ)/chloroquine (CQ) status summary (Plaquenil/Aralen) if taking Plaquenil. It has the examiner annotate Block 60.
Row CDefers to the FAASpecial Issuance
The table lists what to submit to the FAA for review. The examiner defers and submits the information to the FAA for a possible Special Issuance.
If the examiner defers
Show the FAA's words: what the examiner does on each row
- Row A · Examiner can issue
Osteoarthritis that is well controlled, with no persistent daily symptoms, no functional limitations, and treatment with NSAIDs or anti-inflammatory medication only. The table says ISSUE, and has the examiner summarize this history and annotate Block 60.
A. Osteoarthritis … Well controlled, no persistent daily symptoms; No functional limitations; and Treatment is NSAIDS or anti-inflammatory medication only. … ISSUE Summarize this History, annotate Block 60.
- Row B · CACI
Osteoarthritis on additional medication, or autoimmune arthritis. The table sends the examiner to the CACI worksheet for arthritis and says this will require a current, detailed clinical progress note, and the hydroxychloroquine (HCQ)/chloroquine (CQ) status summary (Plaquenil/Aralen) if taking Plaquenil. It has the examiner annotate Block 60.
B. Osteoarthritis on additional medication OR Autoimmune arthritis … See CACI worksheet This will require a current, detailed clinical progress note. and Hydroxychloroquine (HCQ)/ Chloroquine (CQ) Status Summary (Plaquenil/Aralen) if taking plaquenil. … Follow the CACI - Arthritis Worksheet Annotate Block 60.
- Row C · Special Issuance
All others. The row names complications, symptoms, or an underlying cause with complications or systemic disease, etc. The table lists what to submit to the FAA for review. The examiner defers and submits the information to the FAA for a possible Special Issuance.
C. All others … Complications*; Symptomatic; or Underlying cause with complications or systemic disease, etc. … Submit the following to the FAA for review: … DEFER Submit the information to the FAA for a possible Special Issuance.
The CACI worksheet's criteria
Progress note
What your treating physician finds
- Stable on the current regimen, with no changes recommended
- No symptoms, or mild to moderate symptoms with no significant limitations to range of motion, lifestyle or activities
Acceptable causes
- Osteoarthritis
- Autoimmune, limited to rheumatoid (limited to joint), psoriatic, or ankylosing spondylitis
For osteoarthritis the worksheet points to the disposition table and says a CACI may not be required.
Your arthritis medications
One or more of
- Prednisone (an oral steroid), 20 mg/day equivalent or less
- Azathioprine (Imuran)
- Methotrexate (Trexall)
- Sulfasalazine (Azulfidine)
- Hydroxychloroquine or chloroquine (Plaquenil/Aralen), with the status summary
- Any single medication from the list below, after a 2-week ground trial
Post-dose observation time
- None
- Apremilast (Otezla), baricitinib (Olumiant), tofacitinib (Xeljanz), upadacitinib (Rinvoq)
- 4 hours
- Adalimumab (Humira and all biosimilars), certolizumab (Cimzia), etanercept (Enbrel), golimumab (Simponi), anakinra (Kineret), guselkumab (Tremfya), ixekizumab (Taltz), risankizumab (Skyrizi), sarilumab (Kevzara), secukinumab (Cosentyx), tocilizumab (Actemra), ustekinumab (Stelara)
- 24 hours
- Infliximab (Inflect, Remicade, Renflexis), abatacept (Orencia)
- 72 hours
- Rituximab (Rituxan)
Show the FAA's words: the CACI worksheet's criteria for Arthritis
- Stable on the current regimen, with no changes recommended
FAA criterion: the treating physician finds the condition stable on the current regimen, with no changes recommended.
Treating physician finds the condition stable on current regimen and no changes recommended
- No symptoms, or mild to moderate symptoms with no significant limitations
FAA criterion: no symptoms, or mild to moderate symptoms with no significant limitations to range of motion, lifestyle, or activities.
Symptoms [ ] None or mild to moderate symptoms with no significant limitations to range of motion, lifestyle, or activities
- The cause of the arthritis
FAA criterion: the worksheet says acceptable causes are limited to osteoarthritis and/or autoimmune arthritis, to include only rheumatoid (limited to joint), psoriatic, or ankylosing spondylitis. Beside osteoarthritis it points to the Arthritis Disposition Table and says a CACI may not be required.
Cause of Arthritis *Osteoarthritis - see Arthritis Disposition Table CACI may not be required. Acceptable causes are limited to: [ ] Osteoarthritis* and/or [ ] Autoimmune to include only the following: rheumatoid (limited to joint), psoriatic, or ankylosing spondylitis
- Medications from the worksheet's list
FAA criterion: one or more of the following, with or without daily NSAIDs: the oral steroid prednisone at 20 mg/day equivalent or less (the worksheet points to a steroid conversion calculator); azathioprine (Imuran); methotrexate (Trexall); sulfasalazine (Azulfidine); hydroxychloroquine (HCQ)/chloroquine (Plaquenil/Aralen), for which the worksheet points to its status report requirement; or any single medication from the worksheet's list below it, after a 2-week ground trial (the worksheet prints "Any singe medication").
[ ] One or more of the following with or without daily NSAIDs: Oral steroid prednisone 20 mg/day equivalent or less (see steroid conversion calculator) azathioprine (Imuran) methotrexate (Trexall) sulfasalazine (Azulfidine) Hydroxychloroquine (HCQ)/Chloroquine (Plaquenil/Aralen) see status report requirement below** Any singe medication listed below after a 2-week ground trial and:
- A single medication after a 2-week ground trial, and its post-dose observation time
The worksheet's list of single medications, each after a 2-week ground trial, by post-dose observation time. No post-dose observation time: apremilast (Otezla); baricitinib (Olumiant); tofacitinib (Xeljanz); upadacitinib (Rinvoq). A 4-hour post-dose observation time: adalimumab (Humira and all biosimilars), certolizumab (Cimzia), etanercept (Enbrel), golimumab (Simponi), anakinra (Kineret), guselkumab (Tremfya), ixekizumab (Taltz), risankizumab (Skyrizi), sarilumab (Kevzara), secukinumab (Cosentyx), tocilizumab (Actemra), ustekinumab (Stelara). Other post-dose observation times: 72 hours for rituximab (Rituxan), and 24 hours for infliximab (Inflect, Remicade, Renflexis) and for abatacept (Orencia).
Any singe medication listed below after a 2-week ground trial and: No post-dose observation time: PDE4: apremilast (Otezla) JAK: baricitinib (Olumiant); tofacitinib (Xeljanz); upadacitinib (Rinvoq) 4-hour post-dose observation time: TNF: adalimumab (Humira and all biosimilars), certolizumab (Cimzia), etanercept (Enbrel), golimumab (Simponi) IL: anakinra (Kineret), guselkumab (Tremfya), ixekizumab (Taltz), risankizumab (Skyrizi), sarilumab (Kevzara), secukinumab (Cosentyx), tocilizumab (Actemra), ustekinumab (Stelara) Other post-dose observation time: 72-hour rituximab (Rituxan) 72-hour - CD20 24 hours: infliximab (Inflect, Remicade, Renflexis) - TNF 24 hours: abatacept (Orencia) – T-Cell
If the examiner defersSpecial Issuance
The table's last row is All others. It names complications, symptoms, or an underlying cause with complications or systemic disease, etc., and the table marks it DEFER.
What the FAA lists to send
- Item 1. A current, detailed clinical progress note generated from a clinic visit with the treating physician no more than 90 days before the exam. The table says it must include a detailed summary of the history of the condition; current medications, dosage, and side effects (if any); physical exam findings; results of any testing performed; diagnosis; assessment; plan (prognosis); and follow-up. It should note if there are any functional limitations.
- Item 2. Operative notes, if applicable.
- Item 3. Copies of the imaging reports and lab results, if the treating physician has already performed them.
Show the FAA's words: if the examiner defers
When the examiner defers
- Reason 1
The table's last row is All others. It names complications, symptoms, or an underlying cause with complications or systemic disease, etc., and the table marks it DEFER.
All others • Complications*; • Symptomatic; or • Underlying cause with complications or systemic disease, etc. … DEFER Submit the information to the FAA for a possible Special Issuance.
What the FAA lists to send
- Item 1
A current, detailed clinical progress note generated from a clinic visit with the treating physician no more than 90 days before the exam. The table says it must include a detailed summary of the history of the condition; current medications, dosage, and side effects (if any); physical exam findings; results of any testing performed; diagnosis; assessment; plan (prognosis); and follow-up. It should note if there are any functional limitations.
A current, detailed Clinical Progress Note generated from a clinic visit with the treating physician no more than 90 days before the AME exam. It must include a detailed summary of the history of the condition; current medications, dosage, and side effects (if any); physical exam findings; results of any testing performed; diagnosis; assessment; plan (prognosis); and follow-up. It should note if there are any functional limitations.
- Item 2
Operative notes, if applicable.
Operative notes (if applicable); and
- Item 3
Copies of the imaging reports and lab results, if the treating physician has already performed them.
Copies of imaging reports and lab (if already performed by treating physician)
After the FAA decides
AASIThe AASI sheet for arthritis and/or psoriasis says an FAA physician makes the first decision and grants the Authorization. After that, the sheet says the examiner may reissue under the Authorization when the pilot provides what it lists. The table says follow-up issuance will be per the pilot's own authorization letter.
Show the FAA's words: after the FAA decides
An FAA physician provides the initial certification decision and grants the Authorization in accordance with 14 CFR 67.401 . … Examiners may re-issue an airman medical certificate under the provisions of an Authorization, if the applicant provides the following:
Follow up Issuance Will be per the airman's authorization letter.
What a Special Issuance is
The Guide says an Authorization for Special Issuance, valid for a specified period, may be granted at the Federal Air Surgeon's discretion to a person who does not meet the established medical standards, if the person shows to the satisfaction of the Federal Air Surgeon that the duties authorized by the class of certificate applied for can be performed without endangering public safety during the period the Authorization would be in force.
How the FAA pathways workAt later examsAASI
- First and second class
- Every year
- Third class
- At each required exam
The worksheet says first- and second-class applicants must provide this information every year, and third-class applicants must provide it with each required exam.
Show the FAA's words: how often the FAA asks again
Applicants for first- or second- class must provide this information annually; applicants for third-class must provide the information with each required exam.
Under an FAA Authorization, the AASI sheet lists what the pilot provides for the examiner to reissue. That is the Authorization itself; the type of arthritis or psoriasis; a general assessment of the condition and its effect on daily activities; the name and dosage of the medications used for treatment and/or prevention, with comment regarding side effects; and, for arthritis, comments regarding range of motion of the neck, upper and lower extremities, hands, etc.
Show the FAA's words: at later exams
Examiners may re-issue an airman medical certificate under the provisions of an Authorization, if the applicant provides the following: … An Authorization granted by the FAA; … The type of arthritis or psoriasis; … A general assessment of condition and effect on daily activities; … The name and dosage of medication(s) used for treatment and/or prevention with comment regarding side effects; and … For arthritis - comments regarding range of motion of neck, upper and lower extremities, hands, etc.
What AASI is
AASI stands for AME Assisted Special Issuance. The Guide describes it as a process that lets the examiner reissue a certificate under the provisions of an Authorization for Special Issuance, to an applicant who has a medical condition that is disqualifying under 14 CFR part 67.
How the FAA pathways workThe Authorization granted by the FAA
The AASI sheet's list for a reissue begins with the Authorization the FAA granted.
Show the FAA's words: The Authorization granted by the FAA
Examiners may re-issue an airman medical certificate under the provisions of an Authorization, if the applicant provides the following: … An Authorization granted by the FAA;
The type, a general assessment, and the medications with side effects
The AASI sheet asks for the type of arthritis or psoriasis; a general assessment of the condition and its effect on daily activities; and the name and dosage of the medications used for treatment and/or prevention, with comment regarding side effects.
Show the FAA's words: The type, a general assessment, and the medications with side effects
The type of arthritis or psoriasis; … A general assessment of condition and effect on daily activities; … The name and dosage of medication(s) used for treatment and/or prevention with comment regarding side effects; and
For arthritis, comments on range of motion
For arthritis, the AASI sheet asks for comments regarding range of motion of the neck, upper and lower extremities, hands, etc.
Show the FAA's words: For arthritis, comments on range of motion
For arthritis - comments regarding range of motion of neck, upper and lower extremities, hands, etc.
What the Authorization letter comes with
The AASI sheet says the Authorization letter comes with attachments that specify the information the treating physicians must provide for the reissue determination.
Show the FAA's words: What the Authorization letter comes with
The Authorization letter is accompanied by attachments that specify the information that treating physician(s) must provide for the re-issuance determination.
When the examiner defers a reissue
The AASI sheet says the examiner must defer to the AMCD or Region if the pilot has developed any associated systemic manifestations; for arthritis, if new joints have become involved; if the pilot required a change in the medication used for control of the disease; or if the pilot is taking steroid doses equivalent to more than 20mg of prednisone per day (the sheet points to a steroid conversion calculator).
Show the FAA's words: When the examiner defers a reissue
The Examiner must defer to the AMCD or Region if: … The applicant has developed any associated systemic manifestations; … For arthritis - new joints have become involved; … The applicant required change in medication used for control of the disease; or … The applicant is taking steroids doses equivalent to more than 20mg of prednisone per day ( steroid conversion calculator ).
Good to know
Points from the FAA's own documents that are easy to miss.
What a progress note must include
In most cases it should come from a visit with the treating physician no more than 90 days ago, and cover the history, medications with dosages and side effects, exam findings, test results, diagnosis, assessment and plan, prognosis and follow-up. The FAA's sheet says to make sure the physician adds the prognosis. A portal note or an After Visit Summary that does not meet these criteria is not enough, and neither is a simple "ok to fly" letter. The FAA's documents also call it a status report.
Show the FAA's words: good to know, 1
your patient portal to print out “notes” or an “After Visit Summary (AVS).” … Patient Portal notes or an AVS that do not meet the criteria listed below for a detailed Clinical Progress Note are NOT sufficient for FAA purposes. … To be “current,” in MOST CASES, the detailed Clinical Progress Note should be from an evaluation in which you saw your treating physician no more than 90 days ago. … It Must include the following items: … A summary of the history of the condition, … Current medications, dosages, and side effects (if any); … Clinical exam findings; … Results of any testing performed; … Diagnosis; … Assessment and Plan; … Prognosis (This item may not be on a standard progress note, make sure your physician adds this information.); and … Follow-up … Please note: A letter stating, “Mr. Smith is ok to fly” (or any other simple note), is NOT a current, detailed Clinical Progress Note and is NOT acceptable. … You may also see this called a “current status report” or “status report” in current FAA Guidance. Any reference to a “status report” equals the criteria listed on this sheet.
Osteoarthritis may not require a CACI
Well-controlled osteoarthritis, with no persistent daily symptoms, no functional limitations, and NSAIDs or anti-inflammatory medication only, has its own row, which the table marks ISSUE. Beside osteoarthritis, the worksheet says a CACI may not be required.
Show the FAA's words: good to know, 2
A. Osteoarthritis • Well controlled, no persistent daily symptoms; • No functional limitations; and • Treatment is NSAIDS or anti-inflammatory medication only. ISSUE
*Osteoarthritis - see Arthritis Disposition Table CACI may not be required.
Three autoimmune causes on the worksheet
The worksheet limits the autoimmune causes it accepts to rheumatoid (limited to joint), psoriatic, or ankylosing spondylitis.
Show the FAA's words: good to know, 3
Acceptable causes are limited to: [ ] Osteoarthritis* and/or [ ] Autoimmune to include only the following: rheumatoid (limited to joint), psoriatic, or ankylosing spondylitis
Three statements for Block 60
The examiner must note one of three in Block 60: CACI qualified arthritis, where documents need not go to the FAA; has current or previous SI/AASI but now CACI qualified; or NOT CACI qualified, deferred, with supporting documents submitted.
Show the FAA's words: good to know, 4
AME MUST NOTE in Block 60 one of the following: … CACI qualified arthritis. (Documents do not need to be submitted to the FAA.) … Has current OR previous SI/AASI but now CACI qualified arthritis. … NOT CACI qualified arthritis. I have deferred. (Submit supporting documents.)
The first AASI is deferred to the FAA
For a first-time AASI application for this condition, with all the medical information needed for a determination, the AASI sheet says the examiner must defer and submit all of it to the AMCD or RFS for the initial determination.
Show the FAA's words: good to know, 5
If this is a first-time application for an AASI for the above disease/condition, and the applicant has all the requisite medical information necessary for a determination, the Examiner must defer and submit all of the documentation to the AMCD or RFS for the initial determination.
FAA sources
Every FAA document this page relies on, with the FAA's own date and the date Crosscheck last read it. The documents to print open at the FAA, so they are always the FAA's current ones.
- Open to print: CACI – Arthritis Worksheet, a PDF at the FAA, in a new tab
- Arthritis Disposition TableOpen to print: Arthritis Disposition Table, a PDF at the FAA, in a new tab
Examiner can issue, Special Issuance
- AASI – Arthritis and/or PsoriasisOpen to print: AASI – Arthritis and/or Psoriasis, a page at the FAA, in a new tab
The sheet the examiner follows to reissue under an FAA Authorization.
AASI
- Open at the FAA: Plaquenil Status Report (hydroxychloroquine / chloroquine), a PDF at the FAA, in a new tab
- Open at the FAA: Pilot Information – What a Detailed Clinical Progress Note must contain, a PDF at the FAA, in a new tab
Related conditions
Each has its own page, with what the FAA's documents say about it.
Medication guidance
Medications Crosscheck lists as taken for arthritis, each with its own page on what published FAA guidance says about it.
Hydroxychloroquine and chloroquine
Medication on the FAA's arthritis worksheet
This reports what the FAA has published. It is not medical advice, and it does not say how the FAA or an examiner will decide a case.